ACON · XBRL financial data
Aclarion financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ACON's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | 60 | 75 | 46 | 76 |
| Cost of revenue | 65 | 76 | 85 | 69 |
| Gross profit | (5) | (0) | (39) | 7 |
| Research and development | 1,068 | 873 | 889 | 1,034 |
| General and administrative | 3,991 | 3,245 | 3,609 | 4,125 |
| Total operating expenses | 5,557 | 4,876 | 5,474 | 7,059 |
| Operating income (loss) | (5,562) | (4,876) | (5,513) | (7,052) |
| Interest expense | 1,508 | 608 | 64 | — |
| Other income (expense) | 1 | (1) | 0 | (5) |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 |
| Net income (loss) | (7,069) | (4,911) | (6,993) | (7,234) |
| Earnings per share, basic USD per share | (1.23) | (8.82) | (7,480.00) | (13.61) |
| Earnings per share, diluted USD per share | (1.23) | (8.82) | (7,480.00) | (13.61) |
| Weighted average shares, basic thousands of shares | 6,106 | 557 | 1 | 532 |
| Weighted average shares, diluted thousands of shares | 6,106 | 557 | 1 | 532 |
- † Share count changed about 1/12 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ACON's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,473 | 1,021 | 454 | 12,016 |
| Accounts receivable | 19 | 13 | 18 | 30 |
| Prepaid and other current assets | 200 | 245 | 342 | 316 |
| Total current assets | 1,701 | 1,289 | 824 | 12,397 |
| Property and equipment, net | 3 | 2 | 5 | 24 |
| Total assets | 2,915 | 2,460 | 2,123 | 13,672 |
| Accounts payable | 462 | 761 | 532 | 333 |
| Accrued liabilities | 36 | — | — | — |
| Total current liabilities | 689 | 3,188 | 1,153 | 837 |
| Total deposits | — | — | 464 | — |
| Total liabilities | — | 3,188 | 1,153 | 837 |
| Accumulated deficit | (39,370) | (44,282) | (51,262) | (58,496) |
| Total stockholders' equity | 2,226 | (728) | 970 | 12,835 |
| Total liabilities and equity | 2,915 | 2,460 | 2,123 | 13,672 |
| Common shares outstanding (cover page) thousands of shares | 7,862 | 7,154 | 582 | 2,282 |
- † Share count changed about 1/12 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ACON's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (7,069) | (4,911) | (6,993) | (7,234) |
| Stock-based compensation | 1,187 | 456 | 287 | 105 |
| Depreciation and amortization | — | 163 | 193 | 227 |
| Net cash from operating activities | (4,949) | (3,647) | (5,272) | (7,164) |
| Purchases of property and equipment | — | 0 | 5 | 22 |
| Net cash from investing activities | (208) | (120) | (322) | (204) |
| Proceeds from issuing common stock | 8,552 | 0 | 0 | 5,703 |
| Proceeds from issuing equity | 8,552 | — | 6,600 | — |
| Net cash from financing activities | 6,187 | 3,315 | 5,026 | 18,945 |
- † Share count changed about 1/12 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Aclarion | 16,285 | 25 | (2,657)* | 2.9M | 6.1 quarters | 10-QJun 30, 2026 |
| BioNexus Gene Lab | 1,233 | 76 | (422)* | 2.9M | 2.9 quarters | 10-QJun 30, 2026 |
| Advanced Biomed | 386 | year only | (583)* | 1.7M | 0.7 quarters | 10-KJun 30, 2026 |
| Ludwig Enterprises | 18 | not reported | (153) | 167.2M | 1.3 quarters | 10-QMar 31, 2026 |
| CapForce | 144 | 50,000 | (618)* | 12.4M | 0.2 quarters | 10-QJun 30, 2026 |
| American Shared Hospital Services | 6,511 | 8,430 | 2,236* | 6.7M | — | 10-QJun 30, 2026 |
| Biodesix | 29,996 | 26,861 | (1,562)* | 10.6M | 19.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.